This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2020-2021.
Company Filing History:
Years Active: 2020-2021
Title: Chikwendu Ibebunjo: Innovator in Antibody Research
Introduction
Chikwendu Ibebunjo is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and fusion proteins. With a total of 2 patents, his work has the potential to impact various therapeutic applications.
Latest Patents
Chikwendu's latest patents include innovative advancements in the field of anti-transforming growth factor beta 2 (TGF-β2) antibodies. This invention provides human monoclonal antibodies that preferentially bind to the human TGF-β2 isoform over the TGF-β1 or TGF-β3 isoforms. Additionally, he has developed a soluble alpha klotho and serum albumin fusion protein. This disclosure relates to compositions and methods involving an alpha sKlotho variant or fragment, which may have specific mutations and deletions, enhancing its therapeutic potential.
Career Highlights
Chikwendu Ibebunjo is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis focuses on innovative solutions in the biotechnology sector, contributing to the advancement of medical science.
Collaborations
Throughout his career, Chikwendu has collaborated with esteemed colleagues such as Donglin Guo and Carsten Jacobi. These collaborations have fostered a productive environment for research and development, leading to significant advancements in their respective fields.
Conclusion
Chikwendu Ibebunjo's contributions to antibody research and biotechnology exemplify the innovative spirit of modern science. His patents and collaborations highlight the importance of teamwork in achieving groundbreaking advancements in healthcare.